Alphamab Oncology Doses First Patient in Phase III Cervical Cancer Trial
Alphamab Oncology has dosed the first patient in a Phase III cervical cancer trial of JSKN033.
Related stories
Nasdaq Trading Halt Continues
Nasdaq trading remains halted; the reason is not available.
M impact | EQUITY | Oct 29, 2026, 03:34 PM UTC
Nasdaq halts trading for volatility pause
Nasdaq trading was paused for volatility at 11:34 a.m.
M impact | EQUITY | Oct 29, 2026, 03:34 PM UTC
IIFL Capital launches Sagility block deal worth up to $249.6 million
The offer price could be around Rs 42.45 per share, at a discount to Sagility's October 29 close. Sagility B.V. is expected to be the seller, sources told Moneycontrol.
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
DoorDash to Acquire Instacart in $17 Billion Deal
DoorDash has agreed to acquire Maplebear, Instacart’s parent, in a $17 billion deal. The headline also says quarterly results topped views.
H impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Summi Group Delays Publication of FY26 Annual Results
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC
Xsolla Acquires GamePix to Expand Game Distribution
Xsolla said it acquired web games platform GamePix to expand web and AI-created game distribution.
M impact | EQUITY | Oct 29, 2026, 03:31 PM UTC